ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy
Journal article
SAMMONS E., (2024), Ophthalmology
ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy
Journal article
SAMMONS E. et al, (2023), Ophthalmology
Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial
Journal article
HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial
Journal article
Judge P. et al, (2023), Lancet Diabetes and Endocrinology
Impact of new cardiovascular events on quality of life and hospital costs in people with cardiovascular disease in the UK and US
Journal article
MIHAYLOVA B. et al, (2023), Journal of the American Heart Association
ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
Journal article
SAMMONS E. et al, (2023), Contemporary Clinical Trials Communications
Empagliflozin in Patients with Chronic Kidney Disease
Journal article
HERRINGTON W. et al, (2022), New England Journal of Medicine
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
Journal article
HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur Heart J, 43, 1416 - 1424
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Journal article
HERRINGTON W., (2022), Nephrology, Dialysis and Transplantation
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612
Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2021), The Lancet
The Effects of Anacetrapib on Occlusive Vascular Events During Post-Trial Follow-Up of the REVEAL Randomized Trial
Conference paper
Sammons E. and Grp REVEALSC., (2019), CIRCULATION, 140, E971 - E971
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Journal article
ASCEND Study Collaborative Group None. et al, (2018), The New England journal of medicine, 16, 1529 - 1539
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Journal article
ASCEND Study Collaborative Group None., (2018), The New England journal of medicine
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Journal article
Bowman L. et al, (2017), New England Journal of Medicine
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
Journal article
Landray MJ. and REVEAL Collaborative Group None., (2017), American Heart Journal, 187, 182 - 190
Solitary metastasis of cervical carcinoma to the kidney: A case report and review of the literature
Journal article
Hutchings DC. et al, (2009), UroToday International Journal, 2
Are baroreflex events detected by invasive and non-invasive techniques coincident?
Journal article
Smith SM. et al, (2008), Clinical Physiology and Functional Imaging, 28, 262 - 269
Continuous estimates of dynamic cerebral autoregulation: influence of non-invasive arterial blood pressure measurements
Journal article
Panerai RB. et al, (2008), Physiological Measurement, 29, 497 - 513
Influence of non-invasive measurements of arterial blood pressure in frequency and time-domain estimates of cardiac baroreflex sensitivity
Journal article
Smith SM. et al, (2008), Journal of Hypertension, 26, 76 - 82